University of Pittsburgh

Carnegie Mellon University

Allegheny-singer Research Institute

Geza Erdos

Louis D Falo, Jr

O Burak Ozdoganlar

Garth David Ehrlich

John Gladitz

Fen Z Hu

Patricia Antalis

Marcel Pierre Bruchez

Phil G Campbell

Jonathan W Jarvik

Andrea Gambotto

Eun Kim

Louis Falo

Provided herein are devices and methods used to produce tattoo biosensors that are based on spatially controlled intracutaneous gene delivery of optical reporters driven by specific transcription factor pathways for a given cytokine or other analyte. The biosensors can be specific to a given analyte, or more generically represent the convergence of several cytokines into commonly shared intracellular transcription factor pathways. These biosensors can be delivered as an array in order to monitor multiple cytokines. Biosensor redeployment can enable chronic monitoring from months to years. The tattooed biosensor array of the present invention includes endogenous reporter cells, naturally tuned to each patient's own biology and can be used to reliably measure the state of a patient in real-time.

Biosensor tattoos and uses therefor for biomarker monitoring

A method of forming a microneedle array can include forming a sheet of material having a plurality of layers and micromilling the sheet of material to form a microneedle array. At least one of the plurality of layers can include a bioactive component, and the microneedle array can include a base portion and plurality of microneedles extending from the base portion.

Dissolvable microneedle arrays for transdermal delivery to human skin

A method of forming a microneedle array can include forming a microneedle array that has one or more bioactive component. The microneedle array can include a base portion and plurality of microneedles extending from the base portion, and the one or more bioactive components can be combined with other components to exhibit specific release kinetics when the microneedle array is inserted into the skin of a patient.

Multi-component bio-active drug delivery and controlled release to the skin by microneedle array devices

Microneedle arrays and methods of forming the same can include one or more bioactive components bonded to a biocompatible material such that the one or more bioactive components are cleavable in vivo to release the bioactive component from the biocompatible material.

Bioactive components conjugated to substrates of microneedle arrays

Disclosed is an immunogen comprising a fusion protein, wherein the fusion protein comprises a Zika virus (ZIKV) envelope protein, optionally a signal peptide, and a multimerization domain. The signal peptide is a premembrane (prM) signal peptide, an IgG signal peptide, or a human secretory signal peptide hidden Markov model, and the multimerization domain is an immunoglobulin Fc domain, a T4 fibritin foldon trimerization domain, or a human collagen XV trimerization domain. Nucleic acids, vectors, and microneedle arrays including these compositions are disclosed. Methods of producing an immune response to ZIKV are also disclosed.

Zika virus vaccines

Bioactive components conjugated to dissolvable substrates of microneedle arrays

A method of forming a microneedle array can include forming a microneedle array that has one or more bioactive component. The microneedle array can include a base portion and plurality of microneedles extending from the base portion, and the one or more bioactive components are present in a higher concentration in the plurality of microneedles than in the base portion.

Tip-loaded microneedle arrays for transdermal insertion

A DNA sequence ofclone 151_04 shown in SEQ. ID. NO. 1. A DNA sequence ofclone 125_L2 shown in SEQ. ID. NO. 2. A DNA sequence ofclone 179_D14 shown in SEQ. ID. NO. 3. A DNA sequence ofclone 167_A16 shown in SEQ. ID. NO. 4.

Growing community of inventors

Wexford, PA, United States of America

Geza Erdos